FY2025 · ended Dec 31, 2025 · Revenue $704,000, +63.7% YoY · Filed Mar 19, 2026
Harvard Apparatus Regenerative Technology, Inc. (HRGN) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $704,000 and a net loss of $6.9 million. As of Jun 30, 2026 it held $351,000 in cash and investments and $145,000 in total debt.
Revenue (TTM)
$982,000
+44.6% vs year-ago TTM
Net income (TTM)
$-6.68M
+0.0% vs year-ago TTM
Operating cash flow (TTM)
$-3.63M
+15.4% vs year-ago TTM
Free cash flow
$-4.85M
+30.2% vs prior year
EPS
$-0.67
+15.2% vs prior year
Dividend per share
None
Shares outstanding
17.58M
+10.4% vs prior year
Net cash
$206,000
as of Jun 30, 2026
Operating margin
-683.3%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- HRGN (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Holliston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1563665
- Former names
- Biostage, Inc. (until Jul 10, 2023)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $704,000 | $430,000 | $103,000 | — | $0 |
| Operating income | -$6.9M | -$7.7M | -$9.0M | -$6.2M | -$8.6M |
| Net income | -$6.9M | -$7.7M | -$8.9M | -$6.1M | -$8.0M |
| Diluted EPS | — | — | -$0.67 | — | -$0.79 |
| Operating cash flow | -$3.8M | -$4.9M | -$6.9M | -$5.1M | -$2.6M |
| Free cash flow | — | -$4.9M | -$7.0M | -$5.1M | -$2.6M |
| Total assets | $2.7M | $4.4M | $2.6M | $2.4M | $1.9M |
| Total liabilities | $1.6M | $1.2M | $968,000 | $1.4M | $4.9M |
| Stockholders' equity | $1.1M | $3.2M | $1.6M | -$3.2M | -$3.0M |
| Cash and investments | $1.4M | $2.5M | $1.6M | — | — |
| Total debt | $199,000 | $294,000 | $48,000 | $147,000 | $169,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 14, 2026 | Sep 11, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Aug 3, 2026 | May 8, 2026 |
| 8-K/A |
Amended current report
Material agreement, New debt
|
Aug 3, 2026 | Apr 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 24, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
All 625 Harvard Apparatus Regenerative Technology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.